Home › MetaStat Announces Commencement Of Its Comprehensive Drug Development Program With Significant New Hires And Research Facility Opening
 

Keywords :   


MetaStat Announces Commencement Of Its Comprehensive Drug Development Program With Significant New Hires And Research Facility Opening

2013-10-02 06:24:58| drugdiscoveryonline News Articles

MetaStat Inc., a life science company focused on understanding and treating systemic metastasis, recently announced that it has commenced its comprehensive drug development program with the hiring of Elizabeth Buck, Ph.D. and Matthew O'Connor, both formerly of OSI Pharmaceuticals, Inc. (acquired by Astellas Pharma, Inc.), along with the opening of its new drug discovery research facility located in Stony Brook, NY. Both Dr. Buck and Mr. O'Connor will work closely and in collaboration with Dr. David Epstein, MetaStat's Head of Drug Development and former Chief Scientific Officer of OSI Pharmaceuticals

Tags: research development program significant

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
22.09Atlantic Tropical Weather Outlook
22.09Eastern North Pacific Tropical Weather Outlook
22.09Atlantic Tropical Weather Outlook
22.09Eastern North Pacific Tropical Weather Outlook
22.09Amazon says workers must be in the office. The UK government disagrees. Who is right?
22.09Eastern North Pacific Tropical Weather Outlook
22.09Atlantic Tropical Weather Outlook
21.09Atlantic Tropical Weather Outlook
More »